Patient is currently enrolled in a Novartis-sponsored, Oncology Clinical Development & Medical Affairs study receiving nilotinib and has fulfilled all their requirements in the parent study
Patient is currently benefiting from the treatment with nilotinib, as determined by the investigator
Patient has demonstrated compliance, as assessed by the investigator, with the parent study protocol requirements
Willingness and ability to comply with scheduled visits, treatment plans and any other study procedures
Written informed consent obtained prior to enrolling in roll-over study
NCT01735955_inc_T1
Temporal
currently
NCT01735955_inc_T3
Qualifier
Novartis-sponsored
NCT01735955_inc_T4
Observation
enrolled in a Oncology Clinical Development & Medical Affairs study
NCT01735955_inc_T2
Drug
nilotinib
NCT01735955_inc_T6
Procedure
treatment
NCT01735955_inc_T7
Drug
nilotinib
NCT01735955_inc_T9
Temporal
currently
NCT01735955_inc_T10
Observation
mpliance, th the parent study protocol requirements
W
NCT01735955_inc_T12
Observation
lingness an comply with scheduled visits, t
NCT01735955_inc_T13
Observation
ability to comply with scheduled visits
NCT01735955_inc_T14
Observation
lingness an comply with sc atment plans an
NCT01735955_inc_T15
Observation
Written informed consent
NCT01735955_inc_T16
Temporal
prior to enrolling in roll-over study
NCT01735955_inc_T17
Reference_point
enrolling in roll-over study